ERBB2 and invasive breast carcinoma: Here, we confirm these results, in particular in adjuvant and metastatic patients, also demonstrating correlations to the absence of HER-2/neu and to the presence of ER, findings worthy of further clinical evaluation to demonstrate value as a biomarker in BrCa.